DRD3, but Not BDNF, genotype affects treatment response to paroxetine in major depressive disorder: A preliminary study

Journal of Clinical Psychopharmacology

Volumn 32, Issue 5, 2012, Pages 724-726

  Tsuchimine, Shoko ^a   Yasui Furukori, Norio ^a   Nakagami, Taku ^b   Sato, Yasushi ^c   Kaneko, Sunao ^a  

^a HIROSAKI UNIVERSITY   (Japan)

^b Odate Municipal General Hospital   (Japan)

^c Hirosaki Aiseikai Hospital   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

BRAIN DERIVED NEUROTROPHIC FACTOR; DOPAMINE 3 RECEPTOR; PAROXETINE;

ALLELE; GENETIC POLYMORPHISM; GENOTYPE; HUMAN; LETTER; MAJOR DEPRESSION; PHARMACOGENOMICS; PRIORITY JOURNAL; TREATMENT RESPONSE;

BRAIN-DERIVED NEUROTROPHIC FACTOR; DEPRESSIVE DISORDER, MAJOR; GENOTYPE; HUMANS; PAROXETINE; PHARMACOGENETICS; POLYMORPHISM, SINGLE NUCLEOTIDE; RECEPTORS, DOPAMINE D3; SEROTONIN UPTAKE INHIBITORS; TREATMENT OUTCOME;

EID: 84865861902     PISSN: 02710749     EISSN: 1533712X     Source Type: Journal    
DOI: 10.1097/JCP.0b013e318267b6da     Document Type: Letter

References (8)

1. Guillin O, Diaz J, Carroll P, et al. BDNF controls dopamine D3 receptor expression and triggers behavioural sensitization. Nature. 2001;411:86-89.
2. Guillin O, Griffon N, Bezard E, et al. Brain-derived neurotrophic factor controls dopamine D3 receptor expression: therapeutic implications in Parkinson's disease [review]. Eur J Pharmacol. 2003;480:89-95.
3. Gershon AA, Vishne T, Grunhaus L. Dopamine D2Ylike receptors and the antidepressant response [review]. Biol Psychiatry. 2007;61:145-153.
4. Perlis RH, Adams DH, Fijal B, et al. Genetic association study of treatment response with olanzapine/fluoxetine combination or lamotrigine in bipolar I depression. J Clin Psychiatry. 2010;71: 599-605.
5. Zou YF, Ye DQ, Feng XL, et al. Meta-analysis of BDNF Val66Met polymorphism association with treatment response in patients with major depressive disorder. Eur Neuropsychopharmacol. 2010;20:535-544.
6. Thase ME, Entsuah AR, Rudolph RL. Remission rates during treatment with venlafaxine or selective serotonin reuptake inhibitors. Br J Psychiatry. 2001;178:234-241.
7. Lammers CH, Diaz J, Schwartz JC, et al. Selective increase of dopamine D3 receptor gene expression as a common effect of chronic antidepressant treatments. Mol Psychiatry. 2000;5: 378-388.
8. Sokoloff P, Diaz J, Le Foll B, et al. The dopamine D3 receptor: a therapeutic target for the treatment of neuropsychiatric disorders [review]. CNS Neurol Disord Drug Targets. 2006;5:25-43.